These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
553 related articles for article (PubMed ID: 35674998)
1. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Stubbins RJ; Korotev S; Godley LA Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998 [TBL] [Abstract][Full Text] [Related]
2. Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants. Franco S; Godley LA Gynecol Oncol; 2024 Aug; 187():235-240. PubMed ID: 38823308 [TBL] [Abstract][Full Text] [Related]
3. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes. Singh K; Scalia J; Legare R; Quddus MR; Sung CJ Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781 [TBL] [Abstract][Full Text] [Related]
6. Germline genetic variants in men with prostate cancer and one or more additional cancers. Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667 [TBL] [Abstract][Full Text] [Related]
7. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
8. The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients. Wagener R; Walter C; Auer F; Alzoubi D; Hauer J; Fischer U; Varghese J; Dugas M; Borkhardt A; Brozou T Int J Cancer; 2023 Apr; 152(7):1388-1398. PubMed ID: 36468172 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers. Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281 [TBL] [Abstract][Full Text] [Related]
11. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
15. Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers. Petrackova A; Savara J; Turcsanyi P; Gajdos P; Papajik T; Kriegova E Br J Haematol; 2022 Nov; 199(3):371-381. PubMed ID: 36029002 [TBL] [Abstract][Full Text] [Related]
16. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. West AH; Blazer KR; Stoll J; Jones M; Weipert CM; Nielsen SM; Kupfer SS; Weitzel JN; Olopade OI Fam Cancer; 2018 Oct; 17(4):495-505. PubMed ID: 29445900 [TBL] [Abstract][Full Text] [Related]
17. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081 [TBL] [Abstract][Full Text] [Related]
18. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers. Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants. Schwartz CJ; Khorsandi N; Blanco A; Mukhtar RA; Chen YY; Krings G Breast Cancer Res Treat; 2024 Feb; 204(1):171-179. PubMed ID: 38091153 [TBL] [Abstract][Full Text] [Related]
20. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series. Sukumar J; Kassem M; Agnese D; Pilarski R; Ramaswamy B; Sweet K; Sardesai S Breast Cancer Res Treat; 2021 Apr; 186(2):569-575. PubMed ID: 33507482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]